Related Experiment Video
Updated: Mar 22, 2026
06:31
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
Published on: October 3, 2019
9.3K
Sunscreen sun protection factor claim based on in vivo interlaboratory variability.
International Journal of Cosmetic Science
|April 16, 2016
Summary
The sun protection factor (SPF) claim
Area of Science:
- Dermatology and Cosmetology
- Photoprotection Efficacy Testing
Background:
- The sun protection factor (SPF) is a standard metric for UVB protection, crucial for consumer guidance and product labeling.
- Current regulations permit SPF claims based on a single in vivo test result from one laboratory.
Purpose of the Study:
- To assess the reliability of current in vivo SPF testing for product claims, considering interlaboratory variability.
- To determine if a minimum number of in vivo SPF values from multiple laboratories enhances claim accuracy.
Main Methods:
- Investigated 44 European sunscreen formulations across various product types and SPF categories (15-50+).
- Collected at least three distinct in vivo SPF values for each product from different testing laboratories.
- Performed comprehensive statistical analyses to evaluate interlaboratory variations.
Main Results:
- Significant interlaboratory variability was observed, with coefficients of variation exceeding 50% in some cases.
- The same product could receive disparate SPF claims (e.g., SPF 30, SPF 50, SPF 50+) based on single laboratory results.
- Minimum and maximum in vivo SPF values across laboratories led to differing label claims for identical products.
Conclusions:
- Relying on a single in vivo SPF value significantly compromises the reliability of the final product claim.
- Averaging at least three, ideally four, distinct in vivo SPF values from different laboratories is recommended.
- Mandatory averaging of multiple SPF test results is crucial to mitigate consumer health risks and ensure claim accuracy.
Related Concept Videos
01:20Drug Product Performance: In Vitro–In Vivo Correlation
364
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
364
01:09In Vitro Drug Dissolution: Compendial Testing Models II
498
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
498
01:27Bioavailability Study Design: Absolute Versus Relative Bioavailability
519
Bioavailability is a crucial pharmacokinetic parameter that quantifies the proportion of an administered drug that reaches the systemic circulation and is available for therapeutic action. Regulatory agencies mandate the assessment of bioavailability, typically measured as the area under the drug plasma concentration-versus-time curve (AUC), to ensure the efficacy and safety of pharmaceutical products. These evaluations are categorized as absolute and relative bioavailability studies.Absolute...
519
01:21Testing a Claim about Mean: Unknown Population SD
6.4K
A complete procedure of testing a hypothesis about a population mean when the population standard deviation is unknown is explained here.
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
6.4K
01:13Bioequivalence studies: Biowaivers
380
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
380
01:13In Vitro Drug Dissolution: Compendial Testing Models I
458
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
458